Several porous calcium hydroxyapatite (HA) ceramics have been used clinically as bone substitutes, but most of them possessed few interpore connections, resulting in pathological fracture probably due to poor bone formation within the substitute. We recently developed a fully interconnected porous HA ceramic (IP-CHA) by adopting the 'foam-gel' technique. The IP-CHA had a three-dimensional structure with spherical pores of uniform size (average 150 mm, porosity 75%), which were interconnected by window-like holes (average diameter 40 mm), and also demonstrated adequate compression strength (10-12 MPa). In animal experiments, the IP-CHA showed superior osteoconduction, with the majority of pores filled with newly formed bone. The interconnected porous structure facilitates bone tissue engineering by allowing the introduction of mesenchymal cells, osteotropic agents such as bone morphogenetic protein or vasculature into the pores. Clinically, we have applied the IP-CHA to treat various bony defects in orthopaedic surgery, and radiographic examinations demonstrated that grafted IP-CHA gained radiopacity more quickly than the synthetic HA in clinical use previously. We review the accumulated data on bone tissue engineering using the novel scaffold and on clinical application in the orthopaedic field.
INTRODUCTION
When bone grafts are required for bony defects in orthopaedic surgery, autogenous bone grafting has been the gold standard because of its obvious advantages in osteogenic potential, mechanical properties and the lack of adverse immunological response. On the other hand, autogenous bone grafting has some limitations, such as the requirement of additional surgery for harvesting, the availability of sufficient grafts in size and shape and the risk of donor-site morbidity (Banwart et al. 1995; Arrington et al. 1996) , which may include long-lasting pain, fracture, nerve damage and infection. Although allogeneic bone is widely used in the USA, its use is quite limited in Japan, accounting for as little as 3 per cent of procedures (Prolo & Rodrigo 1985) , presumably owing to religious difficulties with using tissue from other people or corpses, as well as the lack of a well-organized tissue bank system. In addition, allograft carries the risk of transmission of occult disease, or a host immune response, which can sometimes result in complete resorption of the grafts. Therefore, many kinds of biomaterials have been developed as bone substitutes, such as hydroxyapatite (HA), alumina, zirconia, bioglass, polymers, metal, and organic or inorganic bone substitutes (Sartoris et al. 1986; Bucholz et al. 1987; Fujibayashi et al. 2003; .
HA ceramics have been used extensively as a substitute in bone grafts Bucholz et al. 1989) , because the crystalline phase of natural bone is similar to HA. Since the 1980s, blocks and granules of porous calcium HA ceramics (CHA) have been used in orthopaedic, dental or craniofacial surgery (Uchida et al. 1990; Yoshikawa & Uchida 1999; Matsumine et al. 2004) . However, there are few reports which indicate that the pores of implanted CHA are totally filled with newly formed host bone (Nakasa et al. 2005) , probably owing to the closed structures of these CHA with few interpore connections (Ayers et al. 1998) .
Therefore, the development of porous CHA with interpore connections of adequate diameter as well as adequate strength has long been expected as an ideal bone substitute Simon et al. 2003 Simon et al. , 2007 Simon et al. , 2008 . We recently developed a fully interconnected porous HA ceramic (IP-CHA; porosity 75%, average pore size 150 mm and average interconnections 40 mm) by adopting a 'foam-gel' technique, crosslinking polymerization that gelatinizes through the foam-like slurry in a moment (Tamai et al. 2002) . The interconnected porous structure facilitates bone tissue engineering by allowing the introduction of mesenchymal cells, osteotropic agents or vasculature into the pores. In this review, we report a new bone tissue engineering system using IP-CHA, a preliminary clinical result in patients treated with IP-CHA and a new clinical trial using a prefabricated IP-CHA in orthopaedic surgery.
CONVENTIONAL HYDROXYAPATITE CERAMICS IN JAPAN
The crystalline phase of natural bone is basically HA, and HA ceramics have been used extensively as a substitute in bone grafts. The ceramics are available as dense or porous types and the shape types are granular or block-like. Different pore sizes, porosities and strengths are available. Here, we describe four types of conventional HA (the first generation) that were used clinically.
-BONEFIL (Mitsubishi Materials Corporation). The types of ceramics are porous blocks and porous granules, and are most often used in orthopaedics. The sintering temperature is 9008C and the compression strength is 15 MPa/2 to 3 MPa. The pore shape is spongiose and the pore size is 200-300 mm.
The degree of porosity is 60-70 per cent.
The types of ceramics are porous blocks and dense granules, and are most often used in dental surgery. The sintering temperature is 12008C. The pore shape is spongiose and the pore size is 200 mm. All four of these manufactured HA ceramics are without effective interpore connections and essentially non-resorbable.
INTERCONNECTED POROUS HYDROXYAPATITE CERAMICS
The conventional method used to manufacture synthetic porous HA ceramics is by sintering a HA slurry mixed with organic polymer beads (Uchida et al. 1984) . The polymer beads melt and vaporize during the sintering process, eventually leaving pores in the ceramic material. However, the pores resulting from this method are irregular in size and shape and not fully interconnected with one another. Together with Covalent Materials Corporation, MMT Co. Ltd and National Institute for Materials Science, Biomaterials Center, we developed an IP-CHA (porosity 75%, average pore size 150 mm and average interpore connections 40 mm) by adopting the foam-gel technique (figure 1; Tamai et al. 2002) . This approach involves a crosslinking polymerization step that gelatinizes the foam-like CHA slurry in a rapid manner, thus promoting the formation of an interconnected porous structure. Briefly, the new method is as follows.
(i) Slurry preparation: the slurry was prepared by mixing HA (60 wt%) with a crosslinking substrate (polyethyleneimine, 40 wt%).
(ii) Foaming and gelatinization: the slurry was mixed with a foaming agent (polyoxyethylene lauryl ether, 1 wt%) and stirred until the mixture had a foamy appearance. Pore size was controlled by regulating the stirring time. S342 Review. Interconnected porous HA H. Yoshikawa et al.
(iii) Gelatinization: to gelatinize the foamed slurry, another water-soluble crosslinking agent (polyfunctional epoxy compound) was added and the mixture was cast by pouring into a mould. The porous structure stabilized in less than 30 min. The foamy HA gel was removed from the mould, dried and sintered at 12008C. Scanning electron microscopy (SEM) analysis revealed that most of the IP-CHA pores were spherical, similar in size, approximately 100-200 mm in diameter, and showed uniform connections with one another. The wall surface of IP-CHA was very smooth and HA particles were aligned closely to one another and bound tightly.
The majority of the interpore connections ranged from 10 to 80 mm in diameter, with a maximum peak of approximately 40 mm, which would theoretically allow cell migration or tissue invasion from pore to pore (Steinkamp et al. 1976) . Interpore connections larger than 10 mm accounted for as much as 91 per cent of the total porosity in IP-CHA. The calculated available porosity, the proportional volume of pores in the material that were connected by interpore connections larger than 10 mm in diameter, was 73.4 per cent (total porosity)!0.91Z67.1 per cent. The compression strength was 12 MPa, while the compression strength of cancellous bone is 1-12 MPa (Martin et al. 1993) .
OSTEOCONDUCTION IN VIVO
Macroporosity is known to influence the biological performance of calcium phosphate in vivo. Holmes et al. (1988) reported that pores of approximately 100 mm in diameter could provide a framework for bone growth into the pore, which then becomes vascularized easily. Most of the pores of IP-CHA are large enough to show such criteria and, more importantly, the pores are fully interconnected and more likely to allow bone ingrowth.
Cylindrical blocks (6 mm in diameter) of IP-CHA were implanted into rabbit femoral condyle, and the bone ingrowth was histologically analysed (Tamai et al. 2002; Myoui et al. 2004; . Within six weeks after implantation of IP-CHA, mature bone ingrowth was seen in most of the pores throughout the block. In the pores, bone, bone marrow formation through interpore connections with osteoblastic rimming and vessels were all observed (figure 2). We also examined the sequential change in the compression strength of IP-CHA implanted in rabbit femoral condyle. The initial compression strength of IP-CHA was approximately 10-12 MPa. The implanted IP-CHA steadily increased its compression strength with time until nine weeks after implantation, finally reaching a value of approximately 30 MPa (Tamai et al. 2002) .
Recently, in order to reinforce its initial mechanical strength, we have developed a novel composite with the solid form of HA. Figure 3 shows the macroscopic and microscopic images of the solid/interconnected porous HA composite (Kaito et al. 2006) . The mechanical strength of the solid part is 550-570 MPa, thus the solid part may correspond to cortical bone, and the porous part to cancellous bone. We constructed an implant and used a canine lumbar interbody fusion model to evaluate bone conduction of the implant and its efficacy for bony fusion. Six months after the surgery, the implant exhibited almost the same efficacy for bony fusion as iliac bone grafts. Moreover, pores of the porous part of the implant were completely filled with newly formed bone and bone marrow cells (Kaito et al. 2006) .
CLINICAL APPLICATION IN ORTHOPAEDIC SURGERY
HA is a useful material to fill bone defects in treating benign bone tumours because of its biocompatibility, osteoconduction and convenience, and it eliminates the need for additional surgery for harvesting autograft, as we reported previously (Uchida et al. 1990; Yoshikawa & Uchida 1999; Matsumine et al. 2004) . However, as a late complication, pathological fractures of the implanted sites have been reported (Yoshikawa & Uchida 1999; Matsumine et al. 2004) . This is probably due to poor bone ingrowth in the material as a result of poor incorporation of the material into the host bone. We applied IP-CHA as a bone substitute for the treatment of 59 patients with benign bone tumours at the Osaka University Hospital and its affiliated hospitals. The average age of patients was 32 years (range 5-75 years). The tumours were located in the upper extremities in 25 patients, lower extremities in 27 and pelvis in 7. The mean follow-up period was 46 months (range 32-60 months). After adequate removal of the tumours, IP-CHA blocks and/or granules of 2-5 mm in diameter were used to fill the bony defects. We also used IP-CHA to fill 12 cystic lesions with rheumatoid arthritis (Shi et al. 2006) . None of the patients showed any signs of inflammatory reaction, rejection, infection or abnormal results in blood tests. Neither pathological fracture nor deformity was observed at the implanted site based on radiographic examinations during the follow-up period. The radiographic examinations were periodically carried out and revealed that the radiolucent line between the implanted IP-CHA and host bone tended to decrease with time after surgery and eventually disappeared (figure 4). The radiographic density at the implanted site increased with time and the IP-CHA granules appeared to fuse with one another, eventually forming a dense radiopaque shadow. Interestingly, longitudinal bone growth was not disturbed even when IP-CHA was implanted in close proximity to the growth plate of children (figure 5). Gadoliniumenhanced MRI showed a ring enhancement at the periphery of the implant (data not shown) and the area with enhancement advanced towards the centre of the implant, indicating that bone regeneration with blood supply might occur within the IP-CHA. The IP-CHA can be prefabricated into specific sizes and shapes to match bone defects. We did this to make an implant, which was, in advance, planned and reconstructed with a computer-aided design/manufacturing (CAD/CAM) system. A threedimensional image was reconstructed with the CT data of the estimated bony defect, and the IP-CHA was fabricated by a three-dimensional milling machine (Roland DG, MDX-20; figure 6). We have used the prefabricated IP-CHA for various bony defects in orthopaedic surgery, and obtained a satisfactory clinical outcome. S344 Review. Interconnected porous HA H. Yoshikawa et al.
BONE TISSUE ENGINEERING BY MESENCHYMAL STEM CELLS
The IP-CHA can be used as a scaffold for cell-based bone tissue engineering. We tested the efficacy of IP-CHA using a rat subcutaneous model by Ohgushi & Caplan (1999) . Bone marrow cells were collected from the femur of rat and were cultivated in minimal essential medium supplemented with 15 per cent foetal bovine serum. IP-CHA discs (RZ5 mm, hZ2 mm) were soaked in the cell suspension overnight and further cultured in the same medium with b-glycerophosphate, ascorbic acid and dexamethasone for 14 days. The discs were then implanted into the subcutaneous tissue of rats and harvested for two to eight weeks after implantation. All the implants showed bone formation inside the pore areas as evidenced by decalcified histological sections and microcomputed tomography images . At eight weeks after implantation, extensive bone volume was detected not only in the surface pore areas, but also in the centre pore areas of the implants (figure 7). The combination of IP-CHA and mesenchymal cells could be used as an excellent bone graft substitute because of its mechanical properties and capability of bone formation. Recently, we have started a clinical trial with the combination of IP-CHA and autologous mesenchymal cells for bone tissue repair, and already treated 10 patients.
A precise clinical evaluation is necessary, but we believe that bone tissue engineering by IP-CHA offers new approaches to treatment for patients requiring skeletal reconstruction.
BONE TISSUE ENGINEERING BY BONE MORPHOGENETIC PROTEIN
Bone morphogenetic proteins (BMPs) are biologically active molecules capable of inducing new bone formation, and show potential for clinical use in bone defect repair (a) (b) (c) However, an ideal system for delivering BMPs that can potentiate their bone-inducing ability and provide initial mechanical strength and scaffold for bone ingrowth has not yet been developed. We have analysed the efficacy of IP-CHA as a delivery system for recombinant human BMP-2 (rhBMP-2). We combined two biomaterials to construct a carrier/scaffold system for rhBMP-2: IP-CHA and a synthetic biodegradable polymer, poly-D,L-lactic acid-polyethyleneglycol block co-polymer (PLA-PEG; Miyamoto et al. 1993; Saito et al. 2001) . A rabbit radius model was used to evaluate the boneregenerating activity of the rhBMP-2/PLA-PEG/ IP-CHA composite. All bone defects in groups treated with 5 mg of rhBMP-2 were completely fixed with sufficient strength at eight weeks after implantation figure 8) . Using this carrier scaffold system, we reduced the amount of rhBMP-2 necessary for such results to approximately one-tenth of the amount needed in previous studies. Enhancement of bone formation is probably due to the superior osteoconduction ability of IP-CHA and the optimal drug delivery system provided by PLA-PEG. The PLA-PEG/IP-CHA composite is an excellent carrier/scaffold delivery system for rhBMP-2, and strongly encourages the clinical effects of rhBMP-2 in bone tissue regeneration.
BONE TISSUE ENGINEERING BY VASCULAR PREFABRICATION
Vascular network invasion into porous implants is another important aspect of using such materials as bone substitutes for large bone defects or in the construction of tissue-engineered bone, because cells cannot survive farther than a few hundred micrometres from a nutrient supply. The rate of new bone ingrowth into the porous material depends on vascular invasion from the surface of the implant, which is not fast enough in large implants to transport nutrients to cells transplanted in pores of the implant. Therefore, we examined whether prefabrication of IP-CHA with a vascular bundle enhances vascular network invasion into the pores via interpore connections Myoui et al. 2004; .
When an IP-CHA cylindrical block was prefabricated with rat superficial inferior epigastric vessels, vascular invasion in the pores increased in both number and size, when compared with the control, resulting in more abundant fibrous connective tissue formation. Our findings suggest that inserting a vascular bundle into such interconnecting porous implants at the site of implantation supports vascular network invasion, which may eventually enhance bone ingrowth in the implants. Nakasa et al. (2005) reported that prefabrication of vascularized bone graft using a combination of fibroblast growth factor-2 and vascular bundle implantation into IP-CHA led to a satisfactory result in the reconstruction of bony defects.
APPLICATION FOR CARTILAGE REPAIR AND TENDON ATTACHMENT
We have developed a new technology for articular cartilage repair, consisting of a triple composite of rhBMP-2, PLA-PEG and IP-CHA, to induce the regeneration of both subchondral bone and articular cartilage . Full-thickness cartilage defects in the rabbit were filled with the rhBMP-2 (20 mg)/PLA-PEG/IP-CHA composite. At six weeks, subchondral defects were completely repaired by subchondral bone and articular cartilage covering the bone. The regenerated cartilage manifested a hyalinelike appearance, with a columnar organization of chondrocytes and a mature matrix. The novel cell-free technology, the triple composite of rhBMP-2, PLA-PEG and IP-CHA, could mark a new development in the field of articular cartilage repair. Our new strategy for articular cartilage repair seems to be unique for the following three reasons: (i) we used autogenous mesenchymal cells efficiently recruited from bone marrow by strongly activating the regeneration process of the subchondral bone defect, (ii) continuous BMP stimuli seemed to promote both the vigorous regeneration of subchondral bone and the following chondrocytic differentiation and cartilaginous matrix production at the surface resulting in hyaline-like cartilage regeneration in as little as three weeks, and (iii) the regenerated cartilage exhibited almost perfect lateral integration with the surrounding host cartilage, probably because the whole regeneration process in this system was in situ and efficient, unlike an ex vivo chondrocyte culture system. Ito et al. (2008) reported that an osteochondral plug using cultured chondrocytes and cylindrical IP-CHA plugs was successful in treating osteochondral defects in a rabbit model. Ohmae et al.
have also tried to enhance tendon attachment to bone using IP-CHA with bone marrow stromal cells in a rabbit model, and obtained a satisfactory result (Omae et al. 2006 (Omae et al. , 2007 .
CONCLUSIONS
The foam-gel technique is an innovative method that generates a three-dimensional fully interconnected porous structure in synthetic HA ceramics. The interconnected porous structure encourages bone ingrowth into the material and eventually leads to good incorporation of the material into the host bone. Our study indicated that IP-CHA exhibited excellent bone ingrowth in an animal model and favourable performance in clinical use. We believe that IP-CHA is an excellent bone substitute for filling bone defects and should be considered as an alternative to autogenous bone. In addition, IP-CHA seems likely to serve as a good scaffold for cell-based or cytokine-based tissueengineered bone. In fact, we have been successful in bone tissue engineering using rhBMP-2, mesenchymal cells or vasculature in animals. The synthetic scaffold can be prefabricated into specific sizes and shapes to match bone defects, and even into a composite with the solid form of HA in order to reinforce its initial mechanical strength. IP-CHA is now commercially available in Japan, and we have applied IP-CHA as a bone substitute for the treatment of more than 80 patients with benign bone tumours or rheumatoid arthritis, and obtained some favourable clinical results. Recently, we have started a clinical trial with the combination of IP-CHA and autologous mesenchymal cells for bone tissue repair. Additional studies with larger animals including dogs or monkeys and precise clinical evaluation are necessary, but we believe that bone tissue engineering by IP-CHA offers new approaches to the treatment of patients requiring skeletal reconstruction.
